- Poster presentation
- Open Access
Immunization strategies to elicit mucosal immune response of HIV
Retrovirologyvolume 3, Article number: P68 (2006)
Since most human immunodeficiency virus (HIV) infection are initiated following mucosal to the virus, the anatomic containment or abortion of an HIV infection is likely to require vaccine-elicited cellular immune response in those mucosal sites. Studing vaccine-elicited mucosal immune responses have been problematic because of the difficulties associated with sampling T lymphocytes from those anatomic compartments. Herpes simplex virus type 1(HSV-1) infects a wide range of cells, including dendritics cells. Consequently, HSV-1 vectors may be capable of eliciting strong immune responses(Both celluar and humoral immune responses) to HIV.
To test this hypothesis, an HSV-1 amplicon plasmid encoding HIV-1 gp120 was constructed and murine immune response to helper virus-free amplicon were evaluated a sing intramuscular injection of HIV:gp120 amplicon (HSV:gp120)elicited Env-specific cellular and humoral immune response. The immune response to HSV:gp120 was durable, with robust cellular and longer humoral response. Finally, HSV: gp120 elicited significant Env-specific cellular immune response even in animals that had been previously infected with wild-type HSV-1 Taking together, these data strongly support the use of helper-free HSV-1 amplicon particles as vaccine delivery vectors to elicit mucosalimmune response of HIV.